Observed Signal · Sep 15, 2026 · Corporate Update · Source: KFF · Impact: 5/5
FDA Regulation and the Dynamic Nature of AI
KFF released Episode 15 of its podcast 'The Business of Health with Chip Kahn' on September 15, 2026, titled 'FDA Regulation and the Dynamic Nature of AI'. The episode features Dr. Brian Miller, a former FDA official and associate professor at Johns Hopkins University, discussing the challenges of applying the FDA's 1976 medical device framework to adaptive AI technologies. Miller argues that today's manual medicine is less safe than assumed and warns that fear-driven regulation could limit AI's opportunities. The conversation was recorded shortly before the FDA released a discussion paper on possible regulatory approaches.
This episode addresses the critical regulatory question of how the FDA should oversee adaptive AI in healthcare, featuring insights from a former FDA official. It matters to the ecosystem because decisions on AI regulation will directly impact innovation, patient safety, and market access for health AI products.
MARKET SIGNALS
Track KFF Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Key Takeaways & Evidence Grounding
- KFF published the podcast episode 'FDA Regulation and the Dynamic Nature of AI' on September 15, 2026.
- The episode is Episode 15 in the AI Series of 'The Business of Health with Chip Kahn'.
- Guest Dr. Brian Miller is a former FDA official, practicing hospitalist, and associate professor at Johns Hopkins University.
- The discussion examines the FDA's application of its 1976 medical device framework to AI.
- The conversation was recorded shortly before the FDA released a discussion paper on regulatory approaches.
Connected Companies & Entities
“KFF is the publisher of the podcast episode 'FDA Regulation and the Dynamic Nature of AI' as part of its 'The Business of Health with Chip K...”
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Pharma as Model for AI in Regulated Marketing
At Cannes Lions, Tom Richards (global chief creative officer at 21GRAMS, part of Real Chemistry) and Camilla Griffiths (president for Europe at 21GRAMS) told The Drum that the pharmaceutical sector offers a useful blueprint for marketing with AI under tight regulation. They argue that regulatory constraints can sharpen creative briefs and that involving compliance, legal and regulatory teams from the start produces better work. They also warn that AI changes how audiences discover health information — calling AI “an audience in and of itself” — and that brands must prioritise trustworthy, useful guidance to help empowered patients navigate conflicting online advice. The pair suggest healthcare’s regulated experience can help other industries adapt to AI, trust and scrutiny in marketing.
Agentic AI in healthcare means governing action, not just access
New blog post by Dr. Sean Kelly, Chief Medical and Growth Officer and Sr. VP, Customer Strategy, Healthcare, Imprivata, discussing the need to govern AI agent actions in healthcare beyond just access control.
AI Regulation Debate: Congress Blocked, States Advance
This opinion piece critiques the US federal government's inaction on AI regulation, contrasting it with the iterative 'rough consensus and running code' approach that built the internet. It argues that Congress, led by Speaker Mike Johnson, is using industry disagreement as an excuse not to legislate, while the White House, via AI czar David Sacks, champions self-regulation. The article highlights the EU's AI Act, state-level initiatives in 45 US states, and Colorado's recent repeal-and-replace of its AI law as examples of regulatory iteration. It also warns that poorly designed interfaces, as seen with GDPR consent banners, can undermine regulatory intent, and it draws parallels to the social media self-regulation failures exposed by Frances Haugen. The author calls for Congress to act as a competent 'product owner,' shipping narrow, honest rules and revising based on real-world impact.
WATCHLIST & BRIEFINGS
Receive future signals for KFF & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor KFF
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
